Rivastigmine and Huperzine A as Treatments for Cocaine Dependence

Summary

The purpose of this study is to determine the safety and effects of rivastigmine and huperzine A (HupA), potential treatments for cocaine abuse, when used before experimental administration of cocaine, on a number of physical and psychological measures.

Conditions

• Cocaine Dependence
• Cocaine Addiction
• Cocaine Abuse
• Substance Abuse

Interventions

DRUG

Placebo

The placebo groups will receive the same dosage throughout the study.

DRUG

Rivastigmine 3 mg

The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.

DRUG

Huperzine A 0.4 mg

The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.

DRUG

Rivastigmine 6 mg

The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.

DRUG

Huperzine A 0.8 mg

The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Baylor College of Medicine

  lead OTHER

Principal Investigators

• Richard De La Garza, II, PhD · Baylor College of Medicine

Study Design

Allocation

RANDOMIZED

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-01-31

Primary Completion

2014-06-30

Completion

2014-06-30

Countries

• United States

Study Locations